Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biden’s Visit Highlights China-U.S. Cooperation On API Oversight And Patent Protection

This article was originally published in PharmAsia News

Executive Summary

Last week, U.S. Vice President Joe Biden visited China, Japan, and South Korean during a six-day Asia trip. One of Biden’s goals in China was to strengthen collaboration between the two countries on food and drug safety as well as patent protection.

You may also be interested in...



FDA Inspection Growth In China Stymied By Visa Issues

The agency is waiting for approval to locate 10 new drug inspectors in China.

China One Step Closer To Global Standards For Drug Quality With Rollout Of New GMP Guidelines

SHANGHAI - China's State FDA recently issued a note to provincial FDA offices to require pharma companies and active pharmaceutical ingredient producers to file a Common Technical Document when they submit manufacturing applications as an effort to improve drug quality and research and development work in China

U.S. FDA Launches First Overseas Office in Beijing

U.S. HHS Secretary Michael Leavitt and U.S. FDA Commissioner Andrew von Eschenbach officially opened the first overseas FDA office Nov. 19 in Beijing in a continuing effort to improve foreign product safety, while the agency faces criticism from the U.S. Congress

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC083402

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel